4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
C22H25N7O2S — CID 155119030
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (PubChem CID 155119030) has the molecular formula C22H25N7O2S and a molecular weight of 451.56 g/mol. Its IUPAC name is 4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile.
Molecular Properties
| Compound Name | 4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
|---|---|
| PubChem CID | 155119030 |
| Molecular Formula | C22H25N7O2S |
| Molecular Weight | 451.56 g/mol |
| Exact Mass | 451.18 |
| IUPAC Name | 4-(cyclopentylamino)-2-[4-(1,1-dioxothiazinan-2-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| SMILES | N#Cc1c[nH]c2nc(Nc3ccc(N4CCCCS4(=O)=O)cc3)nc(NC3CCCC3)c12 |
| InChI | InChI=1S/C22H25N7O2S/c23-13-15-14-24-20-19(15)21(25-16-5-1-2-6-16)28-22(27-20)26-17-7-9-18(10-8-17)29-11-3-4-12-32(29,30)31/h7-10,14,16H,1-6,11-12H2,(H3,24,25,26,27,28) |
| InChIKey | CKUNUTHFLOEIMI-UHFFFAOYSA-N |
| XLogP | 3.86 |
| TPSA | 126.80 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 451.56 |
| LogP ≤ 5 | 3.86 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155119030 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.